免疫联合靶向治疗巨块型肝细胞癌1例报道

Immuno-and targeted combination therapy in giant hepatocellular carcinoma:a case report

目的:探讨晚期肝癌患者应用免疫联合靶向治疗的有效性及安全性。方法:回顾分析经介入治疗无效后运用免疫联合靶向治疗的患者1例,男性,42岁。初诊、介入治疗及免疫联合靶向治疗后客观影像学证据及甲胎蛋白水平等。结果:(1)临床疗效。患者肿瘤明显缩小、分期显著下降、生存期延长,再次复发后经过放疗及调整靶免方案后患者病情处于稳定状态。(2)安全性。患者用药期间未出现明显的药物副作用级不良事件。结论:免疫联合靶向治疗对部分晚期肝癌患者有效,能显著减小肿瘤大小,使部分患者再次获得外科手术机会或能显著延长晚期肝癌患者生存期,为晚期肝癌患者的综合治疗开启全新篇章。

Objective:To investigate the efficacy and safety of immune combined targeted therapy in patients with advanced liver cancer.Methods:A retrospective analysis was performed for 1 patient,a 42-year-old male,who underwent immune combined targeted therapy after ineffective interventional therapy.Objective imaging evidence and alpha-fetoprotein levels after initial diagnosis,interventional therapy and immune combined targeted therapy.Results:Clinical efficacy.The patient’s tumor was significantly reduced,the stage was significantly reduced,the survival time was prolonged,and the patient’s condition was stable after radiotherapy and adjustment of the target exemption protocol after relapse.Security.There were no significant adverse events of the drug side effect level during the patient’s administration.Conclusion:Immune combined with targeted therapy is effective in some patients with advanced liver cancer,which can significantly reduce tumor size,enable some patients to obtain surgical opportunities again or significantly prolong the survival time of patients with advanced liver cancer,and open a new chapter for the comprehensive treatment of patients with advanced liver cancer.